Cover Image
市場調查報告書

神經膠質母細胞瘤 - 機會分析與預測

OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024

出版商 GlobalData 商品編碼 355918
出版日期 內容資訊 英文 206 Pages
訂單完成後即時交付
價格
Back to Top
神經膠質母細胞瘤 - 機會分析與預測 OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
出版日期: 2015年12月22日 內容資訊: 英文 206 Pages
簡介

多形性神經膠質母細胞瘤,全存活率是1∼2年,是未滿足需求高的疾病。現在,temozolomide和Avastin是標準的治療方法獨佔市場。至2024年,預計許多企業開發治療藥,並且市場擴大。

本報告提供全球神經膠質母細胞瘤市場相關調查,市場未滿足需求,企業的研究開發策略,開發平台趨勢,歐美及日本等各地區趨勢,今後的預測,及打入市場的主要企業簡介等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因及病理學
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 風險因素和合併症
  • 全球的趨勢
    • 7大市場適應趨勢
    • 7大市場存活率
  • 預測方法
  • 腦瘤的流行病學的預測
  • 考察

第5章 目前治療方法

  • 概要
  • 產品簡介:主力品牌
    • Avastin
    • Temozolomide
    • Gliadel
    • Optune

第6章 未滿足需求評估與機會分析

  • 概要
  • 識別有rGBM難治性疾病的患者的新治療方法
  • 有MGMT非甲基化啟動子的患者的更有效的治療方法
  • 腫瘤反應的評價標準
  • GBM患者的類固醇使用削減
  • 預測治療效果的生物標記識別

第7章 研究開發策略

  • 概要
    • 免疫療法的有效性評估
    • 為了改善治療有效性預測,擴大生物標誌物的使用
    • 為了促進更好的癌症疫苗的認證的動向
    • 手術中的治療藥局所給藥
  • 臨床實驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發的潛力藥物
  • 創新的早期方法

第9章 開發平台價值分析

  • 主要開發平台藥物的臨床性基準
  • 主要開發平台藥物的商業性基準
  • 競爭評估
  • top line:10年預測

第10章 附錄

圖表

目錄
Product Code: GDHC053POA

Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB). The GBM market is currently dominated by temozolomide and Avastin which are considered as standards of care in newly diagnosed and recurrent settings, respectively. Between 2014 and 2024, the market is set to undergo substantial growth due to a number companies developing therapies in the late-stage pipeline, which is dominated by immunotherapies. On one hand, the main drivers of growth will be the launch of EGFR-targeting therapies such as Rintega and ABT-414, as well as the checkpoint inhibitor Opdivo. Furthermore, the launch of autologous cell vaccines such as ICT-107 and DCVax-L will also impact the GBM market. On the other hand, the GBM market constrainers remain modest with the increasing cost-consciousness of healthcare providers, and the launch of biosimilar bevacizumab in the 7MM (US, France, Germany, Italy, Spain, UK and Japan).

Highlights

Key Questions Answered

  • The GBM market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of GBM market?
  • The late-stage GBM pipeline has therapies targeting different GBM populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • Current therapies used to treat GBM include temozolomide, Gliadel and Avastin. How will the advent of new therapies change the drug treatment landscape for GBM? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Findings

  • The main driver of the enormous expansion of the GBM market will be the launch of Opdivo for newly diagnosed and recurrent GBM. GlobalData forecasts significant patient uptake for Opdivo which will supersede Avastin to become the SoC in the recurrent setting.
  • The second largest driver will be the launch of Rintega for EGFRvIII positive GBM. Rintega uptake would be partially facilitated by the availability of EGFRvIII companion diagnostics, which help to identify patients most likely to respond to the treatment.
  • The approval of Rintega and Opdivo will partially fulfil key unmet needs in the GBM space: however, many of these unmet needs will still remain even after these agents are launched.
  • Another driver of the GBM market is the increasing incidence of GBM cases within the 7MM. The biggest constrainer of the GBM market is the launch of biosimilar bevacizumab in the 7MM.

Scope

  • Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized GBM therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global GBM therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global GBM therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global GBM therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. 7MM Incidence Trends
    • 4.3.2. 7MM Trends in Relative Survival
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Brain Cancer (2014-2024)
    • 4.5.1. Diagnosed Incident Cases of Brain Cancer
    • 4.5.2. Age-Specific Diagnosed Incidence of Brain Cancer
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of Brain Cancer
    • 4.5.4. Age-Standardized Diagnosed Incidence of Brain Cancer
    • 4.5.5. Five-Year Diagnosed Prevalent Cases of Brain Cancer
    • 4.5.6. Diagnosed Incident Cases of Brain Cancer by Type
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles- Major Brands
    • 5.2.1. Avastin (bevacizumab)
    • 5.2.2. Temozolomide
    • 5.2.3. Gliadel (carmustine wafer)
    • 5.2.4. Optune (NovoTTF-100A)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Identification of New Treatment Options for Patients with rGBM Refractory to Avastin
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. More Efficacious Treatment for Patients with MGMT-Unmethylated Promoters
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Criteria to Evaluate Tumor Response
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Reduce Use of Steroids in GBM Patients
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Biomarkers Predictive of Therapeutic Efficacy
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. R&D Strategies

  • 7.1. Overview
    • 7.1.1. Assessment of Immunotherapy Efficacy in GBM
    • 7.1.2. Increased Use of Biomarkers to Better Predict Treatment Efficacy
    • 7.1.3. Moving Towards Less Cumbersome Cancer Vaccines to Facilitate Approval
    • 7.1.4. Local Administration of Therapeutics During Surgery
  • 7.2. Clinical Trial Design
    • 7.2.1. Clinical Endpoints
    • 7.2.2. Comparator Arms
    • 7.2.3. Combinatory Approach

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Rintega (rindopepimut)
    • 8.2.2. Opdivo (nivolumab)
    • 8.2.3. ABT-414
    • 8.2.4. ICT-107
    • 8.2.5. VB-111
    • 8.2.6. DCVax-L
    • 8.2.7. Toca 511 and Toca FC
    • 8.2.8. Veliparib
    • 8.2.9. ITK-1
    • 8.2.10. Prophage G-100 and G-200
    • 8.2.11. TVI-Brain-1
    • 8.2.12. Cotara (Iodine I 131 Derlotuximab Biotin)
  • 8.3. Innovative Early-stage Approaches
    • 8.3.1. Checkpoint Inhibitors
    • 8.3.2. Vaccines
    • 8.3.3. Small Molecules

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top Line 10-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed GBM Patients
    • 10.4.2. Percent Drug-treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. General Forecast Assumptions
    • 10.4.7. Individual Drug Assumptions
    • 10.4.8. Generic and Biosimilar Erosion
    • 10.4.9. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
    • 10.5.1. High-Prescribing Physician Survey
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Epidemiologist
    • 10.6.3. Therapy Director
    • 10.6.4. Global Director of Therapy Analysis and Epidemiology
    • 10.6.5. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Glioblastoma
  • Table 2: Description of Brain Cancer Types
  • Table 3: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer
  • Table 4: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer
  • Table 5: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 6: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N (Row %), 2014
  • Table 7: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N (Row %), 2014
  • Table 8: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 9: Leading Treatments for Glioblastoma
  • Table 10: Product Profile - Avastin
  • Table 11: Efficacy of Avastin in Phase II Trials
  • Table 12: Efficacy of Avastin Compared to Nitrosureas
  • Table 13: Efficacy of Avastin in Newly Diagnosed GBM
  • Table 14 Avastin SWOT Analysis
  • Table 15: Product Profile - Temozolomide
  • Table 16: Efficacy of Temozolomide in Newly Diagnosed GBM
  • Table 17: Product Profile - Gliadel
  • Table 18: Efficacy of Gliadel in Newly Diagnosed Malignant Glioma Patients
  • Table 19 Overall Unmet Needs - Current Level of Attainment
  • Table 20: Design of Current Phase III Trials in GBM
  • Table 21: Glioblastoma - Late Stage Pipeline, 2015
  • Table 22: Product Profile - Rintega
  • Table 23: Efficacy of Rintega in rGBM
  • Table 24: Rintega SWOT Analysis
  • Table 25: Global Sales Forecast ($m) for Rintega, 2014-2024
  • Table 26: Product Profile - Opdivo
  • Table 27: Preliminary Efficacy of Opdivo Monotherapy and Opdivo + Yervoy Combination Therapy
  • Table 28: Opdivo SWOT Analysis
  • Table 29: Global Sales Forecast ($m) for Opdivo, 2014-2024
  • Table 30: Product Profile - ABT-414
  • Table 31: Preliminary Efficacy of ABT-414 + Temozolomide Rechallenge and ABT-414 Monotherapy
  • Table 32: Safety of ABT-414
  • Table 33: ABT-414 SWOT Analysis
  • Table 34: Global Sales Forecast ($m) for ABT-414, 2014-2024
  • Table 35: Product Profile - ICT-107
  • Table 36: Efficacy of ICT-107 in Phase II Study, Months (N)
  • Table 37: Safety of ICT-107
  • Table 38: ICT-107 SWOT Analysis
  • Table 39: Global Sales Forecast ($m) for ICT-107, 2014-2024
  • Table 40: Product Profile - VB-111
  • Table 41: Efficacy of VB-111
  • Table 42: VB-111 SWOT Analysis
  • Table 43: Global Sales Forecast ($m) for VB-111, 2014-2024
  • Table 44: Product Profile - DCVax-L
  • Table 45: DCVax-L SWOT Analysis
  • Table 46: Global Sales Forecast ($m) for DCVax-L, 2014-2024
  • Table 47: Product Profile - Toca 511 and Toca FC
  • Table 48 Toca 511 and Toca FC SWOT Analysis
  • Table 49: Global Sales Forecast ($m) for Toca 511, 2014-2024
  • Table 50: Global Sales Forecast ($m) for Toca FC, 2014-2024
  • Table 51: Product Profile - Veliparib
  • Table 52 Veliparib SWOT Analysis
  • Table 53: Global Sales Forecast ($m) for Veliparib, 2014-2024
  • Table 54: Product Profile - ITK-1
  • Table 55: Efficacy of ITK-1 in a Phase I trial
  • Table 56: ITK-1 SWOT Analysis
  • Table 57: Global Sales Forecast ($m) for ITK-1, 2014-2024
  • Table 58: Product Profile - Prophage
  • Table 59: Preliminary Efficacy of Prophage G-100 + Temozolomide Combination Therapy
  • Table 60: Prophage G-100 and G-200 SWOT Analysis
  • Table 61: Product Profile - TVI-Brain-1
  • Table 62: TVI-Brain-1 SWOT Analysis
  • Table 63: Product Profile - Cotara
  • Table 64: Cotara SWOT Analysis
  • Table 65: Key Early-Stage Pipeline Products in GBM
  • Table 66 Clinical Benchmark of Key Marketed and Pipeline Drugs - Newly Diagnosed GBM
  • Table 67: Commercial Benchmark of Key Marketed and Pipeline Drugs - Newly Diagnosed GBM
  • Table 68: Commercial Benchmark of Key Marketed and Pipeline Drugs - Recurrent GBM
  • Table 69: Global Sales Forecast ($m) for GBM, 2014-2024
  • Table 70: Key Events Impacting Sales for Glioblastoma, 2014-2024
  • Table 71: GBM Market - Drivers and Barriers, 2014-2024
  • Table 72: Key Launch Dates in the GBM Market, 2014-2024
  • Table 73: Key Patent Expiries in the GBM Market, 2014-2024
  • Table 74: Average Body Weight and Surface Area Across the 7MM
  • Table 75: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Men, 1998-2007
  • Figure 2: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Women, 1998-2007
  • Figure 3: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 4: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N, 2014
  • Figure 5: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N, 2014
  • Figure 6: 7MM, Age-Standardized Diagnosed Incidence of Brain Cancer, All Ages, N, 2014
  • Figure 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 8: 7MM, Diagnosed Incident Cases of Brain Cancer by Type, All Ages, Both Sexes, N, 2014
  • Figure 9: Rintega's Phase II & III Development in Glioblastoma
  • Figure 10: Opdivo's Phase II & III Development in Glioblastoma
  • Figure 11: ABT-414's Phase II & III Development in Glioblastoma
  • Figure 12: ICT-107's Phase II & III Development in Glioblastoma
  • Figure 13: VB-111's Phase II & III Development in Glioblastoma
  • Figure 14: DCVax-L's Phase II & III Development in Glioblastoma
  • Figure 15: Toca 511 and Toca FC's Phase II & III Development in Glioblastoma
  • Figure 16: Veliparib's Phase II & III Development in Glioblastoma
  • Figure 17: ITK-1's Phase II & III Development in Glioblastoma
  • Figure 18: Prophage (G-100 and G-200)'s Phase II & III Development in Glioblastoma
  • Figure 19: TVI-Brain 1's Phase II & III Development in Glioblastoma
  • Figure 20: Cotara's Phase II & III Development in Glioblastoma
  • Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2014-2024
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2014-2024
  • Figure 23: GBM Sales by Product, 2014-2024
Back to Top